Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer
Recruiting now NCT07348887
Run by University Health Network, Toronto · for 18 and older · All sexes
What this study is about
This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancer
Who can join (things the study team will check)
✅ You may be able to join if…
- Age ≥ 18 years
- Histologically proven Squamous Cell carcinoma of head and neck
- Bilateral neck being treated
- At least one level 1b not being treated electively and with no target structure, other than elective level II/III, <1cm to spared SMG
- ECOG PS 0-2
- Planned for curative (chemo)radiotherapy
- Able to receive and understand verbal and written information regarding study and able to give written informed consent
- Be able to lie comfortably on back and to wear immobilization for up to 1 hour
🚫 You may not be able to join if…
- As judged by investigator evidence of systemic disease that makes unsuitable for study
- Pregnancy
- Underlying salivary dysfunction prior to treatment judged by investigator to affect likelihood of benefit from ART
Where this trial is running
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Who to contact
Andrew McPartlin, MD · 416-946-2132 · andrew.mcpartlin@uhn.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07348887.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.